Medtronic (NYSE:MDT) said this week that it’s Resolute Onyx drug-eluting stent will launch in Japan on July 10th.
The device’s predecessor, Resolute Integrity, began selling in Japan in August 2012.
The drug-eluting stent has a metallically dense, radiopaque inner core within the cobalt alloy wire to boost visibility for accurate placement, according to Medtronic. The stent also features thin struts and a polymer blend that minimizes inflammation and risk of stent thrombosis.
“With the new Core Wire Technology, the Resolute Onyx aims for improved deliverability in complex lesions, enhanced conformability to the vessel wall and greater radiopacity for more accurate stent placement,” Dr. Shigeru Saito, one of the investigators of the Resolute Japan study, said in prepared remarks. “The Resolute Onyx will be one of the new standards of durable polymer drug-eluting stent in Japan.”
Medtronic won FDA approval for the Resolute Onyx device in May this year. It also has CE Mark clearance in the European Union.
